Sjögren's Syndrome

Sjögren's syndrome is the association of dry eyes (xerophthalmia) and dry mouth (xerostomia), with polyarthritis. The presence of sicca (dryness) symptoms in the absence of another connective tissue disease is designated 'primary Sjögren's syndrome', whereas their occurrence in association with another autoimmune process, such as rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, or polymyositis, is termed 'secondary Sjögren's syndrome'. Subjectively- decreased tear production can be objectively documented with the Schirmer test. The goals of treatment are to provide symptomatic relief as well as to reduce the risk of long-term damage. Artificial tears, which vary in viscosity, are central to the management of xerophthalmia Hydroxychloroquine has been useful in managing musculoskeletal manifestations and lymphadenopathy Corticosteroids are reserved for more serious or life-threatening major organ system involvement, Methotrexate, azathioprine, and cyclosporine A have been used for their corticosteroid-sparing effects.


In order to proceed further, you need to have an account on IDG.
Create a new account now

Registered users, you can login below to access this page.